Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.50 |
| ▸ | IKZF2 | Q9UKS7 | 4/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | HPGDS | O60760 | 2/20 | 0.45 |
| ▸ | WIZ | O95785 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462404 | 1.00 | CRBN (0.50) | CRBNDDB1IKZF2CSNK1A1HPGDS | |
| SCHEMBL25227480 | 1.00 | CRBN (0.50) | CRBNDDB1IKZF2CSNK1A1HPGDS | |
| SCHEMBL29547522 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30720192 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30720169 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL20046704 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL31611548 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL27301548 | 0.94 | CRBN (0.56) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL20231651 | 0.92 | CRBN (0.53) | CRBNDDB1IKZF2CSNK1A1WIZ | |
| SCHEMBL30942249 | 0.92 | CRBN (0.47) | CRBNDDB1IKZF2CSNK1A1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2022-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485735-B2 | Selective CDK4/6 inhibitor and preparation thereof | CDK4, CDK6, CDK3 | CRBN 835/4885DDB1 615/4885IKZF2 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.